1. Home
  2. INAB vs SINT Comparison

INAB vs SINT Comparison

Compare INAB & SINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IN8bio Inc.

INAB

IN8bio Inc.

HOLD

Current Price

$1.48

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Logo SiNtx Technologies Inc.

SINT

SiNtx Technologies Inc.

HOLD

Current Price

$1.96

Market Cap

11.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
INAB
SINT
Founded
2016
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.7M
11.1M
IPO Year
2020
2007

Fundamental Metrics

Financial Performance
Metric
INAB
SINT
Price
$1.48
$1.96
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$11.00
AVG Volume (30 Days)
50.0K
45.2K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
59.45
EPS
N/A
N/A
Revenue
N/A
$1,018,000.00
Revenue This Year
N/A
$30.26
Revenue Next Year
N/A
$413.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.17
$1.86
52 Week High
$2.73
$6.78

Technical Indicators

Market Signals
Indicator
INAB
SINT
Relative Strength Index (RSI) 46.82 38.89
Support Level $1.34 $1.93
Resistance Level $1.85 $2.98
Average True Range (ATR) 0.08 0.15
MACD -0.00 -0.01
Stochastic Oscillator 60.91 11.11

Price Performance

Historical Comparison
INAB
SINT

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.

About SINT SiNtx Technologies Inc.

SINTX Technologies Inc is an advance ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications. It provides biomedical solutions for medical devices specializing in silicon nitride (Si3N4) for musculoskeletal and antipathogenic applications. It also manufactures silicon nitride parts for customers in the electrical, aerospace, and other industrial sectors. The company is a globalised leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans. The Company operates as one operating segment.

Share on Social Networks: